Hinge Health’s s-1 filing seems to shed a light on DarioHealth’s potential opportunity; With Hinge targeting a potential $3-6B IPO valuation with similar growth metrics, Dario’s comparable 32.9% revenue growth, superior 80%+ gross margins, and multi-condition platform addressing the $1.2 trillion cardiometabolic disease market and $100 billion GLP-1 market create compelling value proposition; Dario currently seems to trade and significantly lower revenue multiples to Hinge’s expected IPO, creating a potential valuation arbitrage opportunity; Recent 398% B2B2C revenue surge and path to profitability by year-end strengthen Dario’s positioning amid renewed interest in the $661 billion MSK and growing digital health sector

Market News Alerts Reports: DarioHealth Corp. (Nasdaq: DRIO)* emerges as a potential hidden gem in digital health as competitor Hinge Health prepares to go public at a multi-billion-dollar valuation, highlighting a dramatic valuation gap that savvy investors are beginning to notice. With Hinge Health filing for a potential April IPO at a valuation that according to recent reports could reach $3-6 billion despite recent market volatility, DarioHealth's comprehensive AI-driven chronic care platform appears to be potentially significantly undervalued by comparison.

Financial analysis reveals striking similarities between the two digital health innovators. Hinge reported $390 million in 2024 revenue with 33% growth and 78% gross margins, while DarioHealth delivered 32.9% revenue growth to $27 million with B2B2C gross margins exceeding 80%. Even at Hinge's more conservative expected IPO valuation of $3 billion, the 7.7x revenue multiple would value DRIO at over $207.9 million compared to its current market cap of approximately $28 million – representing a potential upside of 642%. At the higher end of Hinge's expected valuation range ($6 billion or 15.4x revenue), a similar multiple applied to DRIO would yield a valuation of $415.8 million – suggesting a potential 1,485% upside if the valuation gap were to close.

DarioHealth's recent performance further strengthens the investment case. Its Q4 B2B2C recurring revenue surged 398% year-over-year, driven by rapid adoption across employers and health plans. The company has secured multiple Blue Cross Blue Shield agreements, expanded its GLP-1 weight management solution targeting the rapidly growing $100 billion weight-loss market, and integrated an extensive behavioral health provider network, positioning it for accelerated growth in 2025 with 50% projected client expansion.

The comparison highlights a key advantage for DarioHealth: while Hinge offers an MSK-focused solution within the $661 billion musculoskeletal market, DarioHealth's platform addresses multiple chronic conditions including diabetes, hypertension, weight management, MSK, and behavioral health – providing a more comprehensive offering that spans the $1.2 trillion cardiometabolic disease market. This broader approach delivers greater value to healthcare purchasers seeking to consolidate digital health vendors amid rising healthcare costs.

With its AI-driven technology demonstrating significant clinical outcomes, including a proven 5x ROI for payors, DarioHealth's $34.5 million cash position and path to operational cash flow breakeven by year-end create a unique risk-reward profile ahead of potential sector revaluation sparked by Hinge's public debut.

DarioHealth could represent a potential opportunity to participate in the same trends driving Hinge's expected multi-billion valuation at IPO, but at a fraction of the relative value.

>> Subscribe for More Alerts Here

https://newsletter.page/wallstreetalerts

Recent News from Dario:

• DarioHealth Reports Fourth Quarter and Full year 2024 Financial and Operating Results
• Dario Expands Behavioral Health Offerings to Include a Provider Network Through Strategic Arrangement with Rula
• Dario Signs First Healthcare System as Employer Contract, Expanding Market Presence and Recurring Revenue Growth

* Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by Market News Alerts, a brand which is part of the Wall Street Wire™ network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This report contains and is a form of paid promotional content related to DarioHealth and was produced as part of their paid subscription to Wall Street Wire. This report has not been reviewed or approved by DarioHealth prior to publication. The information in this above news report include the numbers relating to HingeHealth’s IPO are based on publicly available news reports and filings which have not been independantly verified by us. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250323951056/en/